Abstract Background. A 17-year-old white male with Crohn's disease who was receiving
maintenance infusions of the anti-tumor necrosis factor (TNF) agent, infliximab, presented …

A25-year-old woman with ileal Crohn's disease presented with alopecia and a diffuse rash.
The patient had inflammation and stricturing in her ileum and was treated initially with 6 …

Tumor necrosis factor‐α inhibitor‐associated adverse cutaneous reactions are common in
patients with inflammatory bowel disease. Infection‐related dermatoses and psoriasiform …

Background: Tumor necrosis factor (TNF) inhibitors are widely used in pediatric patients with
inflammatory bowel disease, as well as psoriasis. However, there is growing evidence that …

Tumor necrosis factor-α (TNF-α) is a pivotal molecule in the pathogenesis of psoriatic skin
lesions. 1 Although TNF-α antagonists seem to be effective in the treatment of refractory …

Infliximab, the monoclonal antibody to tumor necrosis factor, is indicated for refractory
luminal and fistulizing Crohn's disease and rheumatoid arthritis. Infliximab treatment has …

Crohn's disease (CD) is considered a systemic disease, as it is associated with several
clinical manifestations involving organs outside the alimentary tract. There are numerous …

Anti‐tumour necrosis factor (TNF) agents have demonstrated efficacy in inflammatory bowel
disease (IBD). Cutaneous reactions such as new onset psoriasis or psoriasiform‐like …

Anti‐Tumor Necrosis Factor α–Related Psoriatic Lesions in Children with Inflammatory
Bowel Disease: Case Report and Systematic Literature Review - Romiti - 2016 - Pediatric …

Abstract Background and Aims: Paradoxically, psoriasis or psoriasiform skin lesions induced
or exacerbated by anti-TNF antibodies have been described. Here, we report a series of 13 …